Research

New Biotechnology Promises to “Cure” Type 1 Diabetes Within 5 Years

New Biotechnology Promises to “Cure” Type 1 Diabetes Within 5 Years

A team of medical researchers and several Nobel Prize winners from Betalin Therapeutics in Jerusalem has created a “bio-artificial pancreas” made from — wait for it — pig lung tissue and beta-cells.  How it works The “biological pancreas” is implanted…
Rating the Performance of Popular Diabetes Non-Profits

Rating the Performance of Popular Diabetes Non-Profits

Many in the Type 1 Diabetes community want to work for a cure, but philanthropy is the way most of us can help fund new treatments and cure research. Some charity dollars go further than others, and donors want to…
IFNα Kinoid: A promising vaccine against Type 1 Diabetes

IFNα Kinoid: A promising vaccine against Type 1 Diabetes

Neovacs — www.neovacs.fr — is a French biotech company focused on the development of Kinoids®, therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies, and cancer.  They presented pre-clinical results for T1D its therapeutic vaccine, IFNα Kinoid, during an…
Blood glucose-dependent insulin delivery to simplify treatment

Blood glucose-dependent insulin delivery to simplify treatment

We corresponded with Jingqiang Wang and Professor Zhen Gu of UCLA Engineering about their research on glucose-responsive insulin analogs (ref). The goal of their research is a simple-to-administer system that delivers insulin in a blood glucose-dependent manner. Q1: Is subcutaneous…
Metformin improves insulin sensitivity in overweight/obese adolescents with T1D

Metformin improves insulin sensitivity in overweight/obese adolescents with T1D

We spoke with Kristen Nadeau, MD, MS, (bio) Professor of Pediatrics and Research Director, Pediatric Endocrinology at the University of Colorado SOM about a study that was just published in The Journal of Clinical Endocrinology & Metabolism. Context “Type 1…
Diasome’s Liver Targeted Insulin

Diasome’s Liver Targeted Insulin

We spoke with Robert Geho, CEO of Diasome Pharmaceuticals, Inc. — www.diasome.com — about its nanotechnology additive that delivers insulin to the liver where it can substantially improve T1D glucose control. Normal vs Injected Insulin In normal human physiology, the…
Aaron Kowalski Appointed New JDRF President/CEO

Aaron Kowalski Appointed New JDRF President/CEO

Today, the JDRF announced the appointment of Aaron J. Kowalski, Ph.D., as the nonprofit’s President and Chief Executive Officer. A 15-year veteran of JDRF and the first person living with T1D to lead the research organization, Dr. Kowalski has a…
Oxygen Critical to Practical Islet Transplants

Oxygen Critical to Practical Islet Transplants

We spoke with Klearchos Papas, PhD about his oxygen generator-based islet ‘tea bag’ transplant device for which the JDRF just funded a pre-clinical study (release). Dr. Papas (bio) is a professor in the Departments of Surgery, Medical Imaging, and the…
3D Bio-Printed Bionic Pancreas

3D Bio-Printed Bionic Pancreas

We spoke with Michał Wszoła MD, PhD about the 3D Bio-Printed Bionic Pancreas work being done with his team and Bionic Consortium in Poland. See www.fundacjabirn.pl Problem being Addressed “Pancreatic or pancreatic islet transplantation is the only method to cure…
DRI Poseidon Trial Recruiting Children and Adults

DRI Poseidon Trial Recruiting Children and Adults

We spoke with Camillo Ricordi, MD, Director of the Diabetes Research Institute (DRI) about the Poseidon Trial that is actively recruiting participants. Criteria for Participation DRI is seeking 56 people – 28 adults, and 28 children – to participate in…
A New Paradigm for Type 1 Diabetes Origin

A New Paradigm for Type 1 Diabetes Origin

We spoke with Ajit Shah, PhD and Peter Thompson, PhD about their research which has just been published in Cell Metabolism. This UC San Francisco study of human and mouse pancreatic tissue suggests a new origin story for type 1…
Path to Better Clinical Trials for T1D Delay/Prevention

Path to Better Clinical Trials for T1D Delay/Prevention

The Critical Path Institute (C-Path) is a catalyst in the development of new approaches including biomarkers and modeling and analysis tools to support clinical trial design and clinical outcome assessments. C-Path forms and leads consortiums that include drug developers, academics,…
BCG Vaccine Shows Promising Signals of T1D Efficacy

BCG Vaccine Shows Promising Signals of T1D Efficacy

We spoke with Denise Faustman, MD, Ph.D., Director of Immunobiology Massachusetts General Hospital, and Associate Professor of Medicine Harvard Medical School.  The following is a summary of the research that she and her team are working on. Early Islet Trials I…
T1D Delay/Prevention in at-risk Children

T1D Delay/Prevention in at-risk Children

We spoke with Pieter Rottiers, Ph.D., CEO of ActoBio Therapeutics. Genetic testing, combined with existing NIH TrialNet procedures, has shown very positive results in predicting T1D (see article). Intervention at the earliest possible time is expected to improve outcomes for…
Sernova Cell Pouch Hopes to Improve Islet Transplant Success

Sernova Cell Pouch Hopes to Improve Islet Transplant Success

Sernova is a regenerative medicine company located in London, Ontario. The corporation is led by President and CEO Dr. Philip M. Toleikis (bio) who has a strong background in implantable medical devices from twenty years in leadership roles including Angiotech…
JDRF bets that Pandion Can Help

JDRF bets that Pandion Can Help

We spoke with Anthony Coyle, Ph.D., Co-founder and CEO of Pandion Therapeutics which is located in Cambridge Massachusetts.  This interview was stimulated by the JDRF announcement of their investment in Pandion. Paradigm Change Pandion is trying to shift the paradigm for the treatment…
Vaccine for T1D in Clinical Trials Soon

Vaccine for T1D in Clinical Trials Soon

INTRODUCTION Virus infections have long been considered as a possible cause of type 1 diabetes. One virus group, enteroviruses (EVs), has been studied extensively, and clinical development of a vaccine against T1D-associated EV types has started. “Epidemiological and experimental studies…
Regrowth of Human Beta Cells for T1D and T2D

Regrowth of Human Beta Cells for T1D and T2D

Effective Therapeutic Rate A combination of two drugs enhances the production of beta cells such that they proliferate at the highest rate ever observed in humans – a rate of 5 to 8 percent per day. “Beta cell regeneration is…
Understanding Pancreas Cell Development

Understanding Pancreas Cell Development

Prof. Dr. Henrik Semb who led the study explains his recent paper in Nature. Dr. Semb and his team have discovered the signals that determine the fate of immature cells in the pancreas. The research shows that they are very…
Seraxis Islet Technology Aims for Practical T1D Cure

Seraxis Islet Technology Aims for Practical T1D Cure

Islet transplants offer the hope of a permanent cure for Type 1 Diabetes.  After nearly six years in stealth mode, Seraxis has emerged as a front-runner in the race to clinical islet deployment.  Privately funded, and without any NIH or…
Back to top button